Literature DB >> 35411223

Multicellular tumor spheroids of LNCaP-Luc prostate cancer cells as in vitro screening models for cytotoxic drugs.

Elodie Jouberton1, Aurélien Voissiere2, Frédérique Penault-Llorca1, Florent Cachin1, Elisabeth Miot-Noirault2.   

Abstract

An increasing number of studies concerning solid cancers, including prostate cancer, are tending to demonstrate the predominant role of the interactions of tumor cells with their microenvironment, and underlining the relevance of therapeutic approaches co-targeting these two components. Artificial in vitro 3D culture models, such as spheroids, are therefore being designed to allow intercellular interactions between tumor cells and the matrix, under hypoxic conditions mimicking a microtumor. This project aims to develop and characterize a multicellular tumor spheroid (MCTS) model of human prostate cancer cells expressing PSMA, for in vitro drug screening. To this end, 1,000 cells/well were seeded in 100 µl of culture medium with 0.5% of methylcellulose in 96-well, non-adherent, V-shaped bottom plates. Bioluminescent imaging of the spheroids enabled the measurement of spheroid growth. From Day 7 of growth, immunofluorescence studies showed cellular proliferation (Ki-67), mainly located in the periphery of the spheroid section, associated with the formation of an apoptotic core (TUNEL). Scanning electron microscopy and fluorescent imaging (Lox-1 probe) showed the presence of an extracellular matrix and the installation of an oxygen gradient leading to the formation of a hypoxic area during growth. This hypoxia was correlated with increased VEGF excretion. Drug sensitivity was assessed on 2D and 3D cultures. The LNCaP-Luc spheroids are more resistant to docetaxel and TH-302, a hypoxia-activated prodrug, compared with cells grown in a monolayer. For docetaxel, this resistance increased with the spheroid growth stage, whereas the activity of TH-302 was potentiated by the hypoxic environment. In conclusion, the development of LNCaP-Luc cell MCTS provides a simple model mimicking a microtumor; it appears to be particularly well-suited to the validation of new therapeutic approaches targeting proliferation and the microenvironment. AJCR
Copyright © 2022.

Entities:  

Keywords:  Prostate cancer; hypoxia; spheroid

Year:  2022        PMID: 35411223      PMCID: PMC8984876     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  50 in total

Review 1.  Hypoxia--a key regulatory factor in tumour growth.

Authors:  Adrian L Harris
Journal:  Nat Rev Cancer       Date:  2002-01       Impact factor: 60.716

Review 2.  3D Bioprinting of Tissue/Organ Models.

Authors:  Falguni Pati; Jesper Gantelius; Helene Andersson Svahn
Journal:  Angew Chem Int Ed Engl       Date:  2016-02-19       Impact factor: 15.336

Review 3.  Organoids as an in vitro model of human development and disease.

Authors:  Aliya Fatehullah; Si Hui Tan; Nick Barker
Journal:  Nat Cell Biol       Date:  2016-03       Impact factor: 28.824

Review 4.  Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy.

Authors:  Natalia Baran; Marina Konopleva
Journal:  Clin Cancer Res       Date:  2017-01-30       Impact factor: 12.531

Review 5.  Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis.

Authors:  Peter Vaupel
Journal:  Oncologist       Date:  2008

6.  A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro.

Authors:  Janet Myungjin Lee; Paulette Mhawech-Fauceglia; Nathan Lee; Lucineh Cristina Parsanian; Yvonne Gail Lin; Simon Andrew Gayther; Kate Lawrenson
Journal:  Lab Invest       Date:  2013-03-04       Impact factor: 5.662

7.  Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements.

Authors:  M Höckel; K Schlenger; C Knoop; P Vaupel
Journal:  Cancer Res       Date:  1991-11-15       Impact factor: 12.701

8.  Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro.

Authors:  Brent P Mahoney; Natarajan Raghunand; Brenda Baggett; Robert J Gillies
Journal:  Biochem Pharmacol       Date:  2003-10-01       Impact factor: 5.858

Review 9.  Detection and characterization of tumor hypoxia using pO2 histography.

Authors:  Peter Vaupel; Michael Höckel; Arnulf Mayer
Journal:  Antioxid Redox Signal       Date:  2007-08       Impact factor: 8.401

Review 10.  The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy.

Authors:  Yue Li; Long Zhao; Xiao-Feng Li
Journal:  Front Pharmacol       Date:  2021-04-19       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.